David Benshoof Klein is a healthcare innovator and entrepreneur with more than 20 years of experience in the life science industry and a passion for developing novel patient-centric treatments. In 2012, David recognized the enormous impact of smartphones on behavior and cognition. Driven by the opportunity to leverage software to improve clinical outcomes and bridge gaps in treatment access, he began a journey to develop innovative app-based treatments. He created a term for this new modality of medicine, Digital Therapeutics™, and founded Click Therapeutics which develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. In collaboration with Otsuka, Click Therapeutics developed Rejoyn™, the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms. Click has digital therapeutics under development in a wide variety of therapeutic areas including psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.David is a staunch advocate for rigorous development and high-quality evidence standards. His mission is to create safer and more efficacious treatments especially through the combination of software and drugs, and believes collaborations between tech and pharma will revolutionize the standard of care and improve access to high-quality medical treatments globally. Prior to founding Click Therapeutics, David was Managing Director at Opus Point Partners which created, financed, and operated 10+ science companies including Cougar Biotechnology (Acquired by J&J), Chelsea Therapeutics (Acquired by Lundbeck), and TG Therapeutics (TGTX). He holds a bachelor’s degree from Brandeis University. He was recognized by Goldman Sachs in 2019 as one of the 100 most intriguing entrepreneurs at its annual Builders and Innovators conference, and was honored as a PharmaVoice 100 recipient in October of 2024. David was a guest faculty member at the Biotechnology Program at Columbia University, NYU Stern School of Business, and Columbia Business School. A native New Yorker, David is an avid art enthusiast and is the co-founder of Eli Klein Gallery, America’s leading Chinese contemporary art gallery.